title: Analysis of anti-epileptic drugs in fee-for-service Wisconsin Medicaid.
abstract: BACKGROUND
  Off-label use of prescription drugs presents issues of patient safety and can significantly increase the overall prescription drug expenditure in providing health care services. As a class, the anti-epileptic drugs are provided for off-label use on a frequent basis. Because of the safety issues and increased cost with such prescribing practices, the Wisconsin Medicaid Drug Utilization Review Board (DUR board) reviewed the use of anti-epileptic agents in the fee-for-service Wisconsin Medicaid population.
  
  
  METHODS
  Prescribers with the highest amount paid for drugs in this class, and for which there was no appropriate diagnosis (intervention group), were provided with a list of the patients for whom they prescribed the drug for an off-label clinical condition. A total of 488 prescribers were contacted and informed of the costs and hazards of off-label prescribing.
  
  
  RESULTS
  Using a comparison group of patients who were prescribed anti-epileptic agents but who did not reach the amount paid threshold (non-intervention group), the study demonstrated a decrease of 6652 prescriptions in the intervention group and an increase of 4194 in the non-intervention group. In addition, expenditures for the intervention group dropped by dollar 752,232 and the non-intervention group rose by dollar 835,351. It is estimated that the overall financial impact of this intervention was a savings of dollar 2,552,077 over the 5-month period of review.
authors.affiliation: Division of Health Care Financing APS Healthcare, 10 E Doty St, Suite 210, Madison, WI 53701, USA. mergema@dhfs.state.wi.us
authors.forename: Michael A
authors.initials: MA
authors.lastname: Mergener
authors.forename: Richard M
authors.initials: RM
authors.lastname: Carr
mesh_terms: D000927:Anticonvulsants / Q000191:economics*; D011307:Drug Prescriptions / Q000706:statistics & numerical data; D017723:Drug Utilization Review; D018588:Fee-for-Service Plans; D005252:Fees, Pharmaceutical; D006801:Humans; D008484:Medicaid / Q000191:economics*; D014922:Wisconsin
chemical_list: D000927:Anticonvulsants